Eric Clambey
Concepts (413)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gammaherpesvirinae | 8 | 2021 | 45 | 1.910 |
Why?
| | Herpesviridae Infections | 6 | 2021 | 148 | 1.410 |
Why?
| | CD8-Positive T-Lymphocytes | 13 | 2021 | 932 | 1.300 |
Why?
| | Gene Expression Regulation, Viral | 5 | 2021 | 93 | 1.150 |
Why?
| | T-Lymphocytes, Regulatory | 7 | 2021 | 415 | 1.030 |
Why?
| | B7-H1 Antigen | 5 | 2024 | 246 | 0.830 |
Why?
| | Receptor, Adenosine A2B | 4 | 2013 | 65 | 0.750 |
Why?
| | Immunologic Memory | 8 | 2020 | 370 | 0.710 |
Why?
| | Head and Neck Neoplasms | 7 | 2022 | 569 | 0.700 |
Why?
| | Histocompatibility Antigens Class II | 2 | 2020 | 364 | 0.690 |
Why?
| | Virus Replication | 4 | 2021 | 521 | 0.680 |
Why?
| | RNA, Untranslated | 3 | 2021 | 123 | 0.660 |
Why?
| | Mice | 44 | 2024 | 18491 | 0.650 |
Why?
| | Virus Latency | 6 | 2021 | 93 | 0.650 |
Why?
| | Host-Pathogen Interactions | 3 | 2019 | 366 | 0.640 |
Why?
| | Flow Cytometry | 5 | 2018 | 1172 | 0.630 |
Why?
| | Lung Neoplasms | 7 | 2023 | 2679 | 0.600 |
Why?
| | Gene Expression Regulation, Neoplastic | 4 | 2024 | 1457 | 0.590 |
Why?
| | Virus Activation | 5 | 2021 | 97 | 0.580 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2020 | 174 | 0.580 |
Why?
| | Animals | 56 | 2024 | 38410 | 0.570 |
Why?
| | Immunomodulation | 2 | 2019 | 100 | 0.570 |
Why?
| | Ischemia | 4 | 2015 | 424 | 0.570 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2020 | 288 | 0.560 |
Why?
| | Clone Cells | 3 | 2008 | 263 | 0.520 |
Why?
| | Epigenesis, Genetic | 2 | 2020 | 708 | 0.520 |
Why?
| | Interleukin-10 | 1 | 2019 | 311 | 0.500 |
Why?
| | Tumor Microenvironment | 9 | 2021 | 748 | 0.490 |
Why?
| | Mice, Inbred C57BL | 24 | 2023 | 6041 | 0.490 |
Why?
| | Ikaros Transcription Factor | 2 | 2013 | 23 | 0.470 |
Why?
| | G(M1) Ganglioside | 1 | 2015 | 8 | 0.460 |
Why?
| | Kidney Diseases | 2 | 2020 | 428 | 0.450 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 3 | 2021 | 84 | 0.450 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 2 | 2014 | 334 | 0.450 |
Why?
| | T-Lymphocytes | 4 | 2017 | 2017 | 0.440 |
Why?
| | RNA, Viral | 1 | 2019 | 695 | 0.440 |
Why?
| | Hypoxia | 2 | 2013 | 1208 | 0.430 |
Why?
| | Diagnostic Imaging | 1 | 2018 | 342 | 0.430 |
Why?
| | Drug Resistance, Neoplasm | 4 | 2024 | 889 | 0.430 |
Why?
| | Mice, Transgenic | 10 | 2019 | 2197 | 0.420 |
Why?
| | Killer Cells, Natural | 3 | 2021 | 481 | 0.410 |
Why?
| | Antineoplastic Agents, Immunological | 4 | 2021 | 200 | 0.410 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 3 | 2023 | 244 | 0.400 |
Why?
| | Mice, Knockout | 11 | 2023 | 3153 | 0.400 |
Why?
| | Antibodies | 1 | 2015 | 398 | 0.390 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2018 | 794 | 0.380 |
Why?
| | Forkhead Transcription Factors | 2 | 2019 | 210 | 0.370 |
Why?
| | RNA, Messenger | 2 | 2019 | 2812 | 0.370 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2020 | 1224 | 0.370 |
Why?
| | Interleukin-12 | 1 | 2013 | 115 | 0.370 |
Why?
| | Cisplatin | 2 | 2024 | 347 | 0.360 |
Why?
| | Aging | 5 | 2018 | 1992 | 0.360 |
Why?
| | Gene Expression Regulation | 4 | 2015 | 2625 | 0.340 |
Why?
| | CD4-Positive T-Lymphocytes | 5 | 2020 | 1162 | 0.340 |
Why?
| | Kidney | 5 | 2023 | 1511 | 0.330 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2012 | 300 | 0.330 |
Why?
| | Endotoxins | 1 | 2012 | 217 | 0.330 |
Why?
| | Immunotherapy | 4 | 2021 | 672 | 0.330 |
Why?
| | Neutrophils | 2 | 2017 | 1135 | 0.330 |
Why?
| | Radiation Tolerance | 3 | 2021 | 103 | 0.320 |
Why?
| | Radioimmunotherapy | 2 | 2021 | 25 | 0.320 |
Why?
| | Pneumonia | 3 | 2017 | 636 | 0.310 |
Why?
| | Programmed Cell Death 1 Receptor | 4 | 2020 | 268 | 0.300 |
Why?
| | Cyclins | 2 | 2021 | 79 | 0.280 |
Why?
| | Mice, Inbred BALB C | 8 | 2021 | 1266 | 0.280 |
Why?
| | Open Reading Frames | 2 | 2018 | 130 | 0.270 |
Why?
| | STAT3 Transcription Factor | 2 | 2020 | 215 | 0.270 |
Why?
| | Interferon-gamma | 3 | 2020 | 786 | 0.260 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 3 | 2023 | 1195 | 0.260 |
Why?
| | Signal Transduction | 6 | 2019 | 5272 | 0.260 |
Why?
| | Oxygen | 1 | 2013 | 998 | 0.260 |
Why?
| | Acute Kidney Injury | 2 | 2012 | 880 | 0.260 |
Why?
| | Immunophenotyping | 2 | 2019 | 325 | 0.250 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p18 | 2 | 2018 | 15 | 0.250 |
Why?
| | Intestinal Mucosa | 1 | 2012 | 676 | 0.240 |
Why?
| | Viral Proteins | 4 | 2021 | 353 | 0.240 |
Why?
| | Inflammation | 4 | 2020 | 2920 | 0.230 |
Why?
| | Nuclear Proteins | 2 | 2021 | 745 | 0.230 |
Why?
| | Papillomavirus Infections | 2 | 2022 | 345 | 0.220 |
Why?
| | Dendritic Cells | 2 | 2021 | 510 | 0.210 |
Why?
| | Cell Line, Tumor | 9 | 2024 | 3565 | 0.200 |
Why?
| | Antigens, Viral | 2 | 2021 | 186 | 0.190 |
Why?
| | Disease Models, Animal | 7 | 2020 | 4604 | 0.190 |
Why?
| | Cell Proliferation | 6 | 2020 | 2529 | 0.190 |
Why?
| | Antineoplastic Agents | 3 | 2024 | 2231 | 0.190 |
Why?
| | Immunity, Cellular | 2 | 2019 | 280 | 0.190 |
Why?
| | Lymphocyte Depletion | 2 | 2021 | 133 | 0.190 |
Why?
| | Spleen | 2 | 2002 | 509 | 0.190 |
Why?
| | Cell Separation | 2 | 2018 | 306 | 0.190 |
Why?
| | Humans | 35 | 2024 | 147293 | 0.180 |
Why?
| | Myeloid-Derived Suppressor Cells | 2 | 2020 | 77 | 0.180 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2024 | 102 | 0.180 |
Why?
| | Peritoneal Cavity | 1 | 2002 | 30 | 0.180 |
Why?
| | Polycystic Kidney Diseases | 1 | 2023 | 82 | 0.180 |
Why?
| | Stomach Neoplasms | 1 | 2024 | 128 | 0.180 |
Why?
| | Acute Lung Injury | 2 | 2017 | 312 | 0.170 |
Why?
| | Sequence Deletion | 1 | 2002 | 192 | 0.170 |
Why?
| | Tumor Cells, Cultured | 2 | 2020 | 891 | 0.170 |
Why?
| | Lymphocytic choriomeningitis virus | 2 | 2018 | 36 | 0.170 |
Why?
| | Tryptophan | 1 | 2023 | 183 | 0.170 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2009 | 928 | 0.170 |
Why?
| | Adaptive Immunity | 2 | 2023 | 171 | 0.170 |
Why?
| | RNA Polymerase III | 1 | 2021 | 34 | 0.170 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2024 | 261 | 0.160 |
Why?
| | Immune Tolerance | 2 | 2020 | 386 | 0.160 |
Why?
| | Gamma Rays | 1 | 2020 | 57 | 0.160 |
Why?
| | Epithelial Cells | 3 | 2018 | 1141 | 0.160 |
Why?
| | Cells, Cultured | 5 | 2018 | 4169 | 0.160 |
Why?
| | Aldehyde-Lyases | 1 | 2020 | 3 | 0.160 |
Why?
| | Oligonucleotides, Antisense | 1 | 2020 | 122 | 0.150 |
Why?
| | Thymocytes | 1 | 2020 | 33 | 0.150 |
Why?
| | Splenectomy | 1 | 2020 | 61 | 0.150 |
Why?
| | Ileitis | 1 | 2020 | 33 | 0.150 |
Why?
| | Sphingosine | 1 | 2020 | 47 | 0.150 |
Why?
| | Complement Factor H | 1 | 2020 | 79 | 0.150 |
Why?
| | Discoidin Domain Receptor 2 | 1 | 2019 | 6 | 0.150 |
Why?
| | Lysophospholipids | 1 | 2020 | 80 | 0.140 |
Why?
| | Receptor, EphB4 | 1 | 2019 | 33 | 0.140 |
Why?
| | Cell Line | 7 | 2018 | 2832 | 0.140 |
Why?
| | Ephrin-B2 | 1 | 2019 | 45 | 0.140 |
Why?
| | Promoter Regions, Genetic | 2 | 2021 | 1253 | 0.140 |
Why?
| | Lymphocytic Choriomeningitis | 1 | 2018 | 25 | 0.140 |
Why?
| | Dasatinib | 1 | 2019 | 58 | 0.140 |
Why?
| | Radiosurgery | 1 | 2022 | 400 | 0.140 |
Why?
| | Lymph Nodes | 2 | 2018 | 514 | 0.140 |
Why?
| | Hepatitis A Virus Cellular Receptor 2 | 1 | 2018 | 28 | 0.140 |
Why?
| | Genes, Reporter | 1 | 2019 | 278 | 0.140 |
Why?
| | Neoplasms, Experimental | 1 | 2019 | 167 | 0.140 |
Why?
| | Varicellovirus | 1 | 2018 | 17 | 0.140 |
Why?
| | Monkey Diseases | 1 | 2018 | 25 | 0.130 |
Why?
| | Trans-Activators | 1 | 2020 | 398 | 0.130 |
Why?
| | Neoplasm Proteins | 1 | 2020 | 445 | 0.130 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 156 | 0.130 |
Why?
| | Receptors, Complement | 1 | 2017 | 123 | 0.130 |
Why?
| | Transplantation Tolerance | 1 | 2017 | 39 | 0.120 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2020 | 299 | 0.120 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2020 | 379 | 0.120 |
Why?
| | Green Fluorescent Proteins | 1 | 2018 | 407 | 0.120 |
Why?
| | T-Lymphocyte Subsets | 2 | 2009 | 421 | 0.120 |
Why?
| | Islets of Langerhans Transplantation | 1 | 2017 | 71 | 0.120 |
Why?
| | Down-Regulation | 2 | 2016 | 618 | 0.120 |
Why?
| | Chemokines, CXC | 1 | 2016 | 68 | 0.120 |
Why?
| | Crohn Disease | 1 | 2020 | 262 | 0.120 |
Why?
| | Anti-Inflammatory Agents | 1 | 2020 | 481 | 0.120 |
Why?
| | Blood Substitutes | 1 | 1996 | 27 | 0.120 |
Why?
| | Cytokines | 3 | 2020 | 2086 | 0.120 |
Why?
| | Mice, 129 Strain | 2 | 2013 | 85 | 0.120 |
Why?
| | Cytotoxicity, Immunologic | 4 | 2019 | 224 | 0.110 |
Why?
| | Antigen Presentation | 1 | 2017 | 209 | 0.110 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2021 | 648 | 0.110 |
Why?
| | Immune Evasion | 1 | 2016 | 63 | 0.110 |
Why?
| | Papillomaviridae | 1 | 2016 | 116 | 0.110 |
Why?
| | Precursor Cells, B-Lymphoid | 1 | 2015 | 41 | 0.110 |
Why?
| | Fusion Proteins, bcr-abl | 1 | 2015 | 68 | 0.110 |
Why?
| | Drug Delivery Systems | 1 | 2019 | 381 | 0.110 |
Why?
| | Rhadinovirus | 1 | 2015 | 20 | 0.110 |
Why?
| | Aminopeptidases | 2 | 2024 | 20 | 0.110 |
Why?
| | V(D)J Recombination | 1 | 2014 | 8 | 0.110 |
Why?
| | Complement Activation | 1 | 2017 | 401 | 0.100 |
Why?
| | Biomarkers | 3 | 2024 | 4351 | 0.100 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2015 | 980 | 0.100 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2015 | 169 | 0.100 |
Why?
| | Adenosine | 2 | 2013 | 255 | 0.100 |
Why?
| | Gene Expression | 1 | 2019 | 1481 | 0.100 |
Why?
| | Antiviral Agents | 1 | 2020 | 776 | 0.100 |
Why?
| | Combined Modality Therapy | 3 | 2023 | 1281 | 0.100 |
Why?
| | Liver Neoplasms | 1 | 2020 | 787 | 0.100 |
Why?
| | Mice, Inbred NOD | 1 | 2015 | 616 | 0.100 |
Why?
| | Perioperative Period | 1 | 2013 | 71 | 0.100 |
Why?
| | Hemoglobins | 1 | 1996 | 386 | 0.100 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2015 | 340 | 0.100 |
Why?
| | Virulence Factors | 1 | 2015 | 175 | 0.100 |
Why?
| | Graft Rejection | 1 | 2017 | 523 | 0.100 |
Why?
| | Antigens | 2 | 2020 | 348 | 0.100 |
Why?
| | Lymphocytes, Null | 1 | 2012 | 3 | 0.100 |
Why?
| | Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 1 | 2012 | 27 | 0.090 |
Why?
| | Thymus Gland | 1 | 2014 | 313 | 0.090 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2024 | 939 | 0.090 |
Why?
| | Computational Biology | 1 | 2018 | 677 | 0.090 |
Why?
| | Nerve Growth Factors | 1 | 2013 | 79 | 0.090 |
Why?
| | Thymoma | 1 | 2012 | 38 | 0.090 |
Why?
| | 5'-Nucleotidase | 1 | 2013 | 49 | 0.090 |
Why?
| | Pneumonia, Viral | 1 | 2018 | 387 | 0.090 |
Why?
| | Aspirin | 1 | 1996 | 406 | 0.090 |
Why?
| | Reperfusion | 1 | 2012 | 54 | 0.090 |
Why?
| | Jurkat Cells | 1 | 2012 | 115 | 0.090 |
Why?
| | Intraoperative Complications | 1 | 2013 | 158 | 0.090 |
Why?
| | Adenosine-5'-(N-ethylcarboxamide) | 1 | 2012 | 9 | 0.090 |
Why?
| | Lung | 3 | 2017 | 4141 | 0.090 |
Why?
| | Equilibrative Nucleoside Transporter 1 | 1 | 2012 | 19 | 0.090 |
Why?
| | Pancreatic Neoplasms | 1 | 2020 | 947 | 0.090 |
Why?
| | Intestinal Diseases | 1 | 2012 | 43 | 0.090 |
Why?
| | Antigenic Variation | 1 | 2011 | 12 | 0.090 |
Why?
| | Lymphocyte Activation | 4 | 2020 | 1140 | 0.090 |
Why?
| | Hypoxia-Inducible Factor 1 | 1 | 2012 | 69 | 0.090 |
Why?
| | Moloney murine leukemia virus | 1 | 2011 | 13 | 0.090 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2013 | 199 | 0.090 |
Why?
| | Cell Hypoxia | 1 | 2012 | 249 | 0.090 |
Why?
| | Liver | 1 | 2020 | 1916 | 0.090 |
Why?
| | Mice, Mutant Strains | 1 | 2012 | 303 | 0.090 |
Why?
| | Vaccines, Subunit | 1 | 2011 | 53 | 0.080 |
Why?
| | Perioperative Care | 1 | 2013 | 231 | 0.080 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2012 | 337 | 0.080 |
Why?
| | Hospital Mortality | 1 | 2016 | 1043 | 0.080 |
Why?
| | Nitric Oxide | 1 | 1996 | 892 | 0.080 |
Why?
| | MicroRNAs | 1 | 2017 | 694 | 0.080 |
Why?
| | Viral Envelope Proteins | 1 | 2011 | 98 | 0.080 |
Why?
| | Tumor Suppressor Proteins | 1 | 2013 | 323 | 0.080 |
Why?
| | Gene Expression Profiling | 2 | 2019 | 1794 | 0.080 |
Why?
| | RNA Interference | 1 | 2012 | 477 | 0.080 |
Why?
| | Blotting, Western | 1 | 2013 | 1186 | 0.080 |
Why?
| | Adenocarcinoma | 1 | 2017 | 928 | 0.080 |
Why?
| | Cancer Vaccines | 1 | 2011 | 164 | 0.080 |
Why?
| | Transforming Growth Factor beta | 1 | 2012 | 475 | 0.080 |
Why?
| | Algorithms | 1 | 2018 | 1868 | 0.080 |
Why?
| | Purines | 1 | 2011 | 188 | 0.080 |
Why?
| | Regional Blood Flow | 1 | 2012 | 514 | 0.070 |
Why?
| | Practice Guidelines as Topic | 1 | 2018 | 1598 | 0.070 |
Why?
| | Colitis | 1 | 2012 | 282 | 0.070 |
Why?
| | Sepsis | 1 | 2016 | 671 | 0.070 |
Why?
| | Diabetic Nephropathies | 1 | 2013 | 322 | 0.070 |
Why?
| | Endothelium, Vascular | 1 | 1996 | 959 | 0.070 |
Why?
| | Cell Differentiation | 2 | 2016 | 2054 | 0.070 |
Why?
| | Intestines | 1 | 2012 | 356 | 0.070 |
Why?
| | Female | 13 | 2020 | 80076 | 0.070 |
Why?
| | Integrin alpha4 | 1 | 2008 | 7 | 0.070 |
Why?
| | Interleukin-1 | 1 | 2012 | 961 | 0.070 |
Why?
| | Up-Regulation | 1 | 2011 | 848 | 0.070 |
Why?
| | ErbB Receptors | 2 | 2023 | 638 | 0.070 |
Why?
| | Mice, Nude | 2 | 2020 | 680 | 0.070 |
Why?
| | Models, Immunological | 1 | 2008 | 99 | 0.070 |
Why?
| | Male | 11 | 2020 | 73950 | 0.070 |
Why?
| | Respiratory Mucosa | 1 | 2011 | 324 | 0.070 |
Why?
| | Membrane Proteins | 2 | 2021 | 1171 | 0.070 |
Why?
| | Gastric Mucosa | 1 | 2007 | 54 | 0.060 |
Why?
| | Gene Knockdown Techniques | 2 | 2018 | 334 | 0.060 |
Why?
| | Phenotype | 2 | 2021 | 3216 | 0.060 |
Why?
| | Salmonella enterica | 1 | 2007 | 52 | 0.060 |
Why?
| | Virulence | 2 | 2015 | 286 | 0.060 |
Why?
| | Health | 1 | 2007 | 82 | 0.060 |
Why?
| | Salmonella Infections | 1 | 2007 | 58 | 0.060 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2008 | 751 | 0.060 |
Why?
| | Immunity | 1 | 2007 | 141 | 0.060 |
Why?
| | Polymerase Chain Reaction | 2 | 2021 | 1046 | 0.060 |
Why?
| | Genetic Predisposition to Disease | 1 | 2012 | 2458 | 0.050 |
Why?
| | B-Lymphocytes | 1 | 2009 | 878 | 0.050 |
Why?
| | B7-1 Antigen | 1 | 2023 | 55 | 0.050 |
Why?
| | Herpesvirus 4, Human | 1 | 2024 | 173 | 0.050 |
Why?
| | Antibodies, Monoclonal | 2 | 2022 | 1514 | 0.050 |
Why?
| | Tryptophan Oxygenase | 1 | 2023 | 33 | 0.050 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2023 | 56 | 0.050 |
Why?
| | Viral Plaque Assay | 1 | 2002 | 29 | 0.050 |
Why?
| | Acrylamides | 1 | 2023 | 74 | 0.050 |
Why?
| | Obesity | 1 | 2016 | 3149 | 0.040 |
Why?
| | 3T3 Cells | 1 | 2002 | 157 | 0.040 |
Why?
| | Organoids | 1 | 2024 | 146 | 0.040 |
Why?
| | Kynurenine | 1 | 2023 | 114 | 0.040 |
Why?
| | Aniline Compounds | 1 | 2023 | 120 | 0.040 |
Why?
| | Cell Communication | 2 | 2017 | 329 | 0.040 |
Why?
| | Smoking | 1 | 2009 | 1483 | 0.040 |
Why?
| | Macrophages | 2 | 2019 | 1529 | 0.040 |
Why?
| | Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2021 | 23 | 0.040 |
Why?
| | Luciferases | 1 | 2021 | 155 | 0.040 |
Why?
| | Basic-Leucine Zipper Transcription Factors | 1 | 2021 | 43 | 0.040 |
Why?
| | Postoperative Complications | 1 | 2013 | 3022 | 0.040 |
Why?
| | Transcription, Genetic | 2 | 2020 | 1456 | 0.040 |
Why?
| | Cetuximab | 1 | 2021 | 111 | 0.040 |
Why?
| | Major Histocompatibility Complex | 1 | 2021 | 234 | 0.040 |
Why?
| | Glomerulonephritis, Membranoproliferative | 1 | 2020 | 28 | 0.040 |
Why?
| | Receptors, CCR | 1 | 2020 | 6 | 0.040 |
Why?
| | Bacterial Proteins | 1 | 2007 | 976 | 0.040 |
Why?
| | Immunocompetence | 1 | 2000 | 46 | 0.040 |
Why?
| | Platelet Count | 1 | 2020 | 95 | 0.040 |
Why?
| | Basophils | 1 | 2020 | 52 | 0.040 |
Why?
| | Gene Targeting | 1 | 2000 | 81 | 0.040 |
Why?
| | Lymphocyte Subsets | 1 | 2020 | 78 | 0.040 |
Why?
| | Radiotherapy, Image-Guided | 1 | 2019 | 40 | 0.040 |
Why?
| | Tumor Burden | 1 | 2021 | 327 | 0.040 |
Why?
| | Suppressor of Cytokine Signaling 1 Protein | 1 | 2019 | 12 | 0.040 |
Why?
| | Interferons | 1 | 2021 | 186 | 0.040 |
Why?
| | Mutation | 2 | 2023 | 4130 | 0.040 |
Why?
| | Neoadjuvant Therapy | 1 | 2022 | 474 | 0.040 |
Why?
| | Sequence Analysis, DNA | 1 | 2002 | 780 | 0.040 |
Why?
| | Chemokine CXCL9 | 1 | 2019 | 38 | 0.040 |
Why?
| | Leukocyte Count | 1 | 2020 | 319 | 0.040 |
Why?
| | Neoplasms | 2 | 2024 | 2946 | 0.040 |
Why?
| | Mice, SCID | 1 | 2000 | 369 | 0.040 |
Why?
| | Pyrimidines | 1 | 2023 | 532 | 0.040 |
Why?
| | Transfection | 1 | 2021 | 930 | 0.040 |
Why?
| | Postoperative Period | 1 | 2020 | 351 | 0.040 |
Why?
| | Homeodomain Proteins | 2 | 2013 | 525 | 0.040 |
Why?
| | Indoles | 1 | 2023 | 510 | 0.040 |
Why?
| | Pancreaticoduodenectomy | 1 | 2020 | 149 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2021 | 745 | 0.030 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2019 | 177 | 0.030 |
Why?
| | Myeloid Cells | 1 | 2020 | 150 | 0.030 |
Why?
| | Heterografts | 1 | 2019 | 143 | 0.030 |
Why?
| | Gene Silencing | 1 | 2019 | 203 | 0.030 |
Why?
| | DNA Repair | 1 | 2020 | 256 | 0.030 |
Why?
| | TRPP Cation Channels | 1 | 2018 | 76 | 0.030 |
Why?
| | Lymphocytes | 1 | 2020 | 378 | 0.030 |
Why?
| | Repressor Proteins | 1 | 2021 | 429 | 0.030 |
Why?
| | RNA Transport | 1 | 2017 | 27 | 0.030 |
Why?
| | Antibodies, Blocking | 1 | 2017 | 37 | 0.030 |
Why?
| | Complement C3d | 1 | 2017 | 62 | 0.030 |
Why?
| | Cell Cycle | 1 | 2020 | 600 | 0.030 |
Why?
| | Chemoradiotherapy | 1 | 2019 | 239 | 0.030 |
Why?
| | Macaca mulatta | 1 | 2018 | 187 | 0.030 |
Why?
| | Radiotherapy | 1 | 2018 | 210 | 0.030 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2017 | 88 | 0.030 |
Why?
| | Monocytes | 1 | 2020 | 539 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2019 | 1302 | 0.030 |
Why?
| | Cell Degranulation | 1 | 2016 | 40 | 0.030 |
Why?
| | Arenaviridae Infections | 1 | 2016 | 17 | 0.030 |
Why?
| | Ovalbumin | 1 | 2017 | 194 | 0.030 |
Why?
| | Lectins, C-Type | 1 | 2016 | 61 | 0.030 |
Why?
| | Complement C3 | 1 | 2017 | 188 | 0.030 |
Why?
| | Survival Analysis | 1 | 2020 | 1386 | 0.030 |
Why?
| | Papillomavirus E7 Proteins | 1 | 2016 | 11 | 0.030 |
Why?
| | Immunoglobulin M | 1 | 2017 | 267 | 0.030 |
Why?
| | Granzymes | 1 | 2016 | 50 | 0.030 |
Why?
| | Calcimycin | 1 | 1996 | 36 | 0.030 |
Why?
| | Protein Kinase Inhibitors | 1 | 2023 | 984 | 0.030 |
Why?
| | NG-Nitroarginine Methyl Ester | 1 | 1996 | 49 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2019 | 444 | 0.030 |
Why?
| | Cyclic GMP | 1 | 1996 | 90 | 0.030 |
Why?
| | Renal Artery | 1 | 1996 | 43 | 0.030 |
Why?
| | B-Cell Activating Factor | 1 | 2015 | 21 | 0.030 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2017 | 212 | 0.030 |
Why?
| | Transplantation, Homologous | 1 | 2017 | 422 | 0.030 |
Why?
| | Chemokines | 1 | 2016 | 217 | 0.030 |
Why?
| | Neutralization Tests | 1 | 2015 | 76 | 0.030 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2015 | 64 | 0.030 |
Why?
| | Cell Survival | 1 | 2018 | 1111 | 0.030 |
Why?
| | Immunity, Innate | 1 | 2021 | 840 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2020 | 8430 | 0.030 |
Why?
| | Nitric Oxide Synthase | 1 | 1996 | 234 | 0.030 |
Why?
| | Cyclic AMP | 1 | 1996 | 208 | 0.030 |
Why?
| | Acetylcholine | 1 | 1996 | 209 | 0.030 |
Why?
| | Stem Cell Niche | 1 | 2015 | 58 | 0.030 |
Why?
| | Immunoblotting | 1 | 2015 | 296 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2019 | 1730 | 0.030 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2018 | 679 | 0.030 |
Why?
| | Integrin alpha Chains | 1 | 2014 | 22 | 0.030 |
Why?
| | Interleukin-27 | 1 | 2014 | 13 | 0.030 |
Why?
| | Femoral Artery | 1 | 1996 | 190 | 0.030 |
Why?
| | Toll-Like Receptor 3 | 1 | 2014 | 30 | 0.030 |
Why?
| | Poly I-C | 1 | 2014 | 58 | 0.030 |
Why?
| | CD11b Antigen | 1 | 2014 | 60 | 0.030 |
Why?
| | DNA Primers | 1 | 2015 | 505 | 0.030 |
Why?
| | Toll-Like Receptor 7 | 1 | 2014 | 43 | 0.030 |
Why?
| | Autoimmunity | 1 | 2020 | 935 | 0.030 |
Why?
| | Dogs | 1 | 1996 | 518 | 0.030 |
Why?
| | California | 1 | 2016 | 477 | 0.030 |
Why?
| | In Vitro Techniques | 1 | 1996 | 1049 | 0.030 |
Why?
| | Cell Movement | 1 | 2018 | 966 | 0.030 |
Why?
| | Cellular Senescence | 1 | 2016 | 229 | 0.030 |
Why?
| | Bone Marrow | 1 | 2015 | 310 | 0.030 |
Why?
| | Netrin-1 | 1 | 2013 | 17 | 0.020 |
Why?
| | Gene Deletion | 1 | 2015 | 392 | 0.020 |
Why?
| | Imidazoles | 1 | 2014 | 247 | 0.020 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2016 | 268 | 0.020 |
Why?
| | Mi-2 Nucleosome Remodeling and Deacetylase Complex | 1 | 2012 | 31 | 0.020 |
Why?
| | Adenosine Deaminase | 1 | 2013 | 45 | 0.020 |
Why?
| | Vasodilation | 1 | 1996 | 522 | 0.020 |
Why?
| | Adoptive Transfer | 1 | 2013 | 200 | 0.020 |
Why?
| | Enzyme Inhibitors | 1 | 1996 | 822 | 0.020 |
Why?
| | No-Reflow Phenomenon | 1 | 2012 | 7 | 0.020 |
Why?
| | Nucleoside Transport Proteins | 1 | 2012 | 9 | 0.020 |
Why?
| | Adult | 3 | 2023 | 41405 | 0.020 |
Why?
| | Dipyridamole | 1 | 2012 | 28 | 0.020 |
Why?
| | Receptors, Purinergic P1 | 1 | 2012 | 30 | 0.020 |
Why?
| | Albuminuria | 1 | 2013 | 189 | 0.020 |
Why?
| | Chromosomal Proteins, Non-Histone | 1 | 2012 | 130 | 0.020 |
Why?
| | Chimerism | 1 | 2012 | 35 | 0.020 |
Why?
| | Biomarkers, Tumor | 1 | 2019 | 1339 | 0.020 |
Why?
| | Apoptosis | 1 | 2020 | 2454 | 0.020 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2012 | 73 | 0.020 |
Why?
| | Membrane Glycoproteins | 1 | 2014 | 499 | 0.020 |
Why?
| | Prognosis | 1 | 2020 | 4383 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 1996 | 2030 | 0.020 |
Why?
| | Gastrointestinal Diseases | 1 | 2013 | 222 | 0.020 |
Why?
| | Antigens, CD | 1 | 2014 | 562 | 0.020 |
Why?
| | Nanoparticles | 1 | 2017 | 524 | 0.020 |
Why?
| | Receptors, Purinergic | 1 | 2011 | 20 | 0.020 |
Why?
| | DNA Methylation | 1 | 2016 | 722 | 0.020 |
Why?
| | Disease Progression | 1 | 2018 | 2890 | 0.020 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2011 | 174 | 0.020 |
Why?
| | Chemotaxis | 1 | 2011 | 122 | 0.020 |
Why?
| | Transcriptome | 1 | 2016 | 1059 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2013 | 1371 | 0.020 |
Why?
| | Alleles | 1 | 2012 | 909 | 0.020 |
Why?
| | Inflammasomes | 1 | 2011 | 145 | 0.020 |
Why?
| | Lipopolysaccharides | 1 | 2013 | 863 | 0.020 |
Why?
| | Fibroblasts | 1 | 2015 | 1039 | 0.020 |
Why?
| | Immunoglobulin Class Switching | 1 | 2009 | 21 | 0.020 |
Why?
| | Phagocytosis | 1 | 2011 | 299 | 0.020 |
Why?
| | Age Factors | 1 | 2016 | 3372 | 0.020 |
Why?
| | Inflammation Mediators | 1 | 2011 | 507 | 0.020 |
Why?
| | Aged | 2 | 2020 | 26514 | 0.020 |
Why?
| | Infection Control | 1 | 2009 | 174 | 0.020 |
Why?
| | Epitopes | 1 | 2009 | 475 | 0.020 |
Why?
| | Organ Specificity | 1 | 2007 | 310 | 0.010 |
Why?
| | Myocardial Infarction | 1 | 2013 | 1213 | 0.010 |
Why?
| | Middle Aged | 2 | 2020 | 36821 | 0.010 |
Why?
| | Critical Illness | 1 | 2012 | 907 | 0.010 |
Why?
| | DNA-Binding Proteins | 1 | 2012 | 1488 | 0.010 |
Why?
| | Transcription Factors | 1 | 2012 | 1747 | 0.010 |
Why?
| | Stroke | 1 | 2013 | 1287 | 0.010 |
Why?
| | Vaccines | 1 | 2009 | 389 | 0.010 |
Why?
| | Risk Factors | 1 | 2016 | 11017 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2020 | 17560 | 0.010 |
Why?
| | Vaccination | 1 | 2009 | 1443 | 0.010 |
Why?
|
|
Clambey's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|